Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026

5 October 2026/by Admin

Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy

3 August 2026/by Admin

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

8 April 2026/by Admin

Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities

23 June 2025/by Admin

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

2 June 2025/by Admin

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

21 January 2025/by Admin

Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK

14 November 2024/by Admin

Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy

28 October 2024/by Admin

Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development

1 May 2024/by Admin

Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy

23 January 2024/by Admin

Aravax appoints Annette Leahy as Director of Clinical Operations

21 July 2023/by Admin

Aravax doses first patient in Phase 2 peanut allergy clinical trials

1 June 2023/by Admin